This is an aggregated industry headline. Read the full story at Drug Channels →
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
By Adam J. Fein, Ph.D.Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque: Why Optum Rx Is Accelerating Its Transparency Strategy The Most Important 340B Paper You’ll Ever Read Blue Shield of Cali
By Drug Channels
· May 27, 2026
· via Drug Channels
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact …
The WeekFierceBiotech ↗
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T …
The WeekBriefing
Allogene’s founding CEO steps down, Agios halts development of tebapivat, AbbVie gains approval for Decnupaz, …